Please use a PC Browser to access Register-Tadawul
Get It
BRIEF-Health Canada Approves Keytruda SC™, A Subcutaneous Formulation Of Pembrolizumab Across Multiple Cancer Indications
Merck & Co., Inc. MRK | 115.79 | -0.24% |
Feb 17 (Reuters) - HEALTH CANADA :
HEALTH CANADA APPROVES KEYTRUDA SC™, A SUBCUTANEOUS FORMULATION OF PEMBROLIZUMAB ACROSS MULTIPLE CANCER INDICATIONS
